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Abstract
Background: JAK2V617F is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs) and has
become a valuable marker for diagnosis of MPNs. However, it has also been found in many other hematological
diseases, and some studies even detected the presence of JAK2V617F in normal blood samples. This casts doubt
on the primary role of JAK2V617F in the pathogenesis of MPNs and its diagnostic value.
Methods: In the present study, we analyzed JAK2V617F positivity with 232 normal blood samples and 2663 patient
blood, bone marrow, and amniotic fluid specimens obtained from a clinical genetics laboratory by using a simple
DNA extraction method and a sensitive nested allele-specific PCR strategy.
Results: We found JAK2V617F present in the majority (78%) of MPN patients and in a small fraction (1.8-8.7%) of
patients with other specific hematological diseases but not at all in normal healthy donors or patients with non-
hematological diseases. We also revealed associations of JAK2V617F with novel as well as known chromosomal
abnormalities.
Conclusions: Our study suggests that JAK2V617F positivity is associated with specific hematological malignancies
and is an excellent diagnostic marker for MPNs. The data also indicate that the nested allele-specific PCR method
provides clinically relevant information and should be conducted for all cases suspected of having MPNs as well as
for other related diseases.
Background
Ph- myeloproliferative neoplasms (MPNs) represent a
group of conditions including polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofi-
brosis (PMF) [1]. The major molecular lesion in these
diseases is JAK2V617F, which occurs in approximately
96% of PV, 65% of PMF, and 55% of ET cases [2-7].
Studies demonstrated that transgenic expression or
knock-in of JAK2V617F caused MPN-like phenotype
in mice [8-14]. JAK2V617F has thus become a valuable
marker for diagnosis of MPNs and an excellent target
for therapeutic drug development [15,16]. However,
JAK2V617F has also been found in refractory anemia
with ringed sideroblasts and thrombocytosis, in
patients with Budd-Chiari syndrome, and in sporadic
cases of other hematological diseases including leuke-
mia and myelodysplastic syndrome (MDS) [15-17].
Interestingly, by using a sensitive allele-specific PCR
approach, we screened over 4000 blood samples ran-
domly collected from a Chinese hospital population
and found nearly 1% of samples to be JAK2V617F
positive, although few of them meet the criteria for
diagnosis of MPNs [18]. Intriguingly, a study using a
more sensitive method revealed the presence of
JAK2V617F in around 10% of normal blood samples
[19]. This casts doubt on the primary role of
JAK2V617F in the pathogenesis of MPNs and its diag-
nostic value [17]. In order to more fully define the role
of JAK2V617F in hematological diseases, the current
study analyzed nearly 3000 blood and tissue specimens.
We found JAK2V617F present in the majority of MPN
patients and in a small fraction of patients with other
specific hematological diseases but not at all in healthy
donors or patients with non-hematological diseases.
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Methods
Sample collection and DNA extraction
The patient samples used in the current study were
residual blood, bone marrow, and amniotic fluid pro-
ducts collected for routine fluorescence in situ hybridi-
zation and karyotype analysis done between 2003 and
2006 in the Genetics Laboratory, Department of Pedia-
trics at University of Oklahoma Health Sciences Cen-
ter. De-identified normal blood samples were collected
from health donors subjected to routine physical
exams at local clinical laboratories. Institutional review
board approval was obtained before these samples
were analyzed. White blood cells from the above clini-
cal samples were fixed with acetic acid/methanol (1:3)
a n ds t o r e di nt h es a m es o l u t i o na t- 2 0 ° C .T oi s o l a t e
DNA for PCR analyses, the cells were pelleted by cen-
trifugation, washed with 70% ethanol, and then resus-
pended in a buffer containing 100 mM Tris-HCl
(pH 8.0), 1% (v/v) Tween 20, and 25 μg/ml
proteinase K. After 2 hr incubation at 55°C, the sam-
ples were heat-treated at 95°C for 10 min to inactivate
proteinase K. Then, they were directly used for detec-
tion of JAK2V617F by using a nested allele-specific
PCR method as described below. For the JAK2V617F-
positive samples identified by nested allele-specific
PCR, DNAs were purified from the proteinase K
digests by performing phenol/chloroform extractions.
The purified DNAs were subjected to direct allele-spe-
cific PCR analyses without going through the initial
PCR amplification step.
PCR amplification and analysis of PCR products
JAK2V617F was detected by nested allele-specific PCR
method as described previously [18]. Briefly, initial PCR
amplifications were performed with two primers and
0.5 μl of cell lysates obtained above in a total volume of
20 μl for 35 cycles. For allele-specific PCR, 0.5 μlo ft h e
initial PCR product was used for further PCR amplifica-
tion with allele-specific nested primers (a mixture of 4
primers) for 35 cycles. Taq DNA polymerase was used
for both initial and nested PCR. The PCR products were
resolved on 3% agarose gel, and DNA bands were visua-
lized by staining with ethidium bromide. Gel images
were captured by using the FluorChem SP imaging sys-
tem from Alpha Innotech. Each JAK2V617F-positive
sample was confirmed by performing the allele-specific
PCR analyses with phenol/chloroform-purified DNA
samples. To avoid possible cross-contaminations, con-
trol experiments with water replacing DNA samples
were routinely performed.
Statistical analysis
Statistical analyses were performed by using the Graph-
Pad Prism program. Differences in JAK2V617F percen-
tages and ages were accessed by Fisher’se x a c tt e s t sa n d
t tests, respectively. P values of less than 0.05 (two
tailed) are considered significantly different.
Results and Discussion
Figure 1 illustrates typical results of JAK2V617F detec-
tion by using nested allele-specific PCR. The conditions
strongly favor the detection of the mutant allele with a
sensitivity of about 0.25% JAK2V617F mutation rate
according to our previous studies with standard DNAs
[18]. To rule out possible cross-contaminations asso-
ciated with nested PCR, control experiments were routi-
nely performed with water instead of DNA samples. Of
the roughly 3000 samples analyzed, a total of 2895 gave
rise to PCR products, and 32 of these were identified as
JAK2V617F positive. Samples that failed to give rise to
clear PCR products were excluded from further analysis.
For all the JAK2V617F-positive samples, DNAs were
purified and enriched from the proteinase K digests by
performing phenol/chloroforme x t r a c t i o n s .T h e s ep u r i -
fied DNAs were dissolved in a small volume of water to
give rise to DNA concentrations ranging from 0.02 to
0.2 mg/ml. Upon direct allele-specific PCR analyses,
they all gave rise to JAK2V617F-positive bands and thus
confirmed the results of our initial screening with nested
PCR. Figure 2 shows typical results of a JAK2V617F-
positive sample together with a JAK2V617F-negative
one. Note that direct analysis of non-purified/non-
enriched samples with direct allele-specific PCR failed to
produce any PCR product. Therefore, our nested allele-
specific PCR analyses increase the sensitivity for
Figure 1 Detection of JAK2V617F by allele-specific PCR. Nested
PCR was performed with crude genomic DNA samples as described
in Methods. PCR products were analyzed on 3% agarose and
visualized by ethidium bromide staining. The expected PCR
products are 453 bp (for both JAK2V617F-positive and -negative
alleles), 279 bp (for JAK2V617F-positive allele), and 229 bp (for
JAK2V617F-negative allele). Lane 1 was done with water in place of
genomic DNA samples to rule out possible cross-contaminations.
Lane 11 did not give a clear PCR product and was excluded from
further analysis. Samples 2 and 9 are JAK2V617F-positive, while all
the rest are JAK2V617F-negative.
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ples with low DNA concentrations and poor quality.
Table 1 summarizes the data of our JAK2V617F ana-
lyses. We identified a total of 32 JAK2V617F-positive
cases out of 665 patients with hematological diseases
but not at all in 2230 samples from normal donors and
patients with non-hematological diseases (P < 0.0001).
Within the hematological diseases, the average age of
JAK2V617F-positive patients was significantly higher
than that of JAK2V617F-negative ones (P = 0.003).
Among the 32 JAK2V617F positive samples, 14 were
from MPN patients, representing 78% of total cases in
the group. This is significantly higher than the percen-
tages found in other groups analyzed in this study
(P value < 0.0001). These MPN patients displayed clini-
cal manifestations of polycythemia, thrombocytosis, and/
or splenomegaly. The average age of these JAK2V617F-
positive MPN patients was 69 (ranging from 48-85),
which is consistent with the fact that MPNs mainly
occur in older people. However, the ages of these
JAK2V617F-positive patients were not significantly dif-
ferent from those of JAK2V617F-negative patients (P =
0.3). Of these 14 cases, all but three were shown to have
a normal karyotype. Among the three patients with
chromosomal abnormalities, the first had monosomy 20,
the second lost chromosome Y, and the third displayed
an isochromosome of the entire long arm of chromo-
some 8. Many reports have shown an association of
monosomy 20 with primary myelofibrosis and a loss
of the Y chromosome in male MPN patients [20]. How-
ever, to our knowledge, ours is the first case of isochro-
mosome 8 in MPNs. Interestingly, two of the four
JAK2V617F-negative MPN samples also had chromo-
some abnormalities; one lost chromosome Y, and the
other had a translocation between chromosomes 9 and
12 at breakpoints near 9p21 and 12p12. Note that the
JAK2 gene is located at 9p24.1. It would be interesting
to know if the translocation affects the expression of
JAK2. In all, the data suggests that cytogenetic analysis
continues to provide useful information for the diagno-
sis and treatment of MPNs that cannot be obtained
with JAK2V617F detection alone. Table 2 lists all the
MNP- and JAK2V617F-positive cases with abnormal
karyotypes.
We also found a total of 18 JAK2V617F-positive cases
out of 480 patients (38-81 years old) with leukocytosis,
acute myeloid leukemia (AML), unspecified leukemia,
anemia, and MDS. In contrast, we did not find a single
JAK2V617F-positive case in blood samples from 232
healthy donors with comparable ages (ranging from 45
to 75 years). This suggests a strong association of
JAK2V617F positivity with these hematological diseases
(P value = 0.001). Note that the ages of these normal
donors were not significantl yd i f f e r e n tf r o mt h o s eo f
healthy donors and that there was no significant differ-
ence in the ages of JAK2V617F-positive and -negative
patients for each hematological disease. It should also be
pointed out that leukocytosis and anemia do not neces-
sarily represent specific diseases but rather manifesta-
tions of a number of hematological diseases. We do not
have information regarding precise diagnosis for these
patients. In addition, since about 10% of MPN patients
eventually develop AML [21], some of the JAK2V617F
positivity found in leukemia may be derived from
M P N s .H o w e v e r ,t h e r ew a sn oe v i d e n c et h a ta n yo f
these patients had a previous history of MPNs. Interest-
ingly, more than half of JAK2V617F-positive patients
had chromosomal abnormalities (see Table 2). One leu-
kocytosis patient displayed a deletion of the long arm of
chromosome 16 at breakpoint of 16q23, but this did not
involve the CBFB gene that is frequently rearranged in
AML-M4 [20]. One of the AMLs had a translocation
between chromosomes 8 and 21 at breakpoints of 8q22
and 21q22, which is commonly associated with AML-
M2 [20]. Rare cases of JAK2V617F positivity have
recently been reported in AML-M2 patients [22]. Two
other AML cases had 5q deletion and monosomy 7,
which is frequently found in this disease [20]. Another
case of AML had a deletion of the long arm of chromo-
some 5 at the breakpoint of 5q21, a deletion of the
short arm of chromosome 6 at breakpoint of 6p21.3,
and monosomy 9. Two of the three unspecified leuke-
mia cases showed abnormal karyotypes, one with tris-
omy 8 and the other with trisomy 20. An extra
chromosome 8 is frequently present in AML patients
but trisomy 20 has not been found to be associated with
any particular type of leukemia [20]. Two out of 65 ane-
mia and two out of 111 MDS patients were found to be
Figure 2 Comparison of JAK2V617F detections by using direct
and nested allele-specific PCR with non-purified and purified
DNA samples. Non-purified and phenol/chloroform extraction-
purified DNAs from JAK2V617F-negative (lane A) and JAK2V617F-
positive (lane B) samples were subjected to direct or nested allele-
specific PCR analyses as indicated. The final PCR products were
analyzed on 3% agarose and visualized with ethidium bromide
staining. Note that the direct PCR analyses of purified DNAs and the
nested PCR analyses of non-purified DNAs gave rise to consistent
results while the direct PCR of non-purified DNAs did not yield any
PCR product.
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patients had a preceding MPN. One of the anemia
patients had a normal karyotype, while the other had
trisomy 8, suggesting that the anemia may be associated
with MDS, which often has trisomy 8 [20]. One of the
MDS patients had a deletion of the long arm of chro-
mosome 5 at breakpoint 5q31.
We also analyzed a total of 98 lymphoma cases. Interest-
ingly, three were found to be JAK2V617F positive, though
all had a normal karyotype. JAKV617F-positive lymphoma
cases were also found in our previous studies with the
Chinese population [18]. The pathological significance of
this finding, however, needs further investigation since
JAK2V617F is not thought to affect lymphocytes [15,16].
Table 1 Results of JAK2V617F Tests










Blood and Bone Marrow Specimens
Hematological diseases 665 32 4.8* 52.8 64.6**
Ph- MPNs 18 14 78* 62.3 69.2
Leukocytosis 23 2 8.7* 50.8 62.5
Acute myeloid leukemia 113 6 5.3* 47.9 56.8
Leukemia (unspecified) 70 3 4.3* 47.1 66.6
Anemia 65 2 3.1* 54 76.8
Lymphoma 98 3 3.1* 55.6 60.2
MDS and probable MDS 111 2 1.8 55.8 49.9
Acute lymphoblastic leukemia 21 0 0 13 -
Chronic lymphocytic leukemia 14 0 0 67.4 -
Chronic myeloid leukemia 32 0 0 47.9 -
Multiple myeloma 50 0 0 65.1 -
Thrombocytopenia 29 0 0 60.1 -
Other hematological diseases 21 0 0 54.4 -
Non-hematological diseases 1731 0 0 7.3 -
Developmental disorders 1370 0 0 4.9 -
Multiple miscarriage/infertility 83 0 0 30.2 -
Others 278 0 0 14.8 -
Normal samples 232 0 0 54.5 -
Amniotic Fluid Specimens
Cytogenetic screening 267 0 0 31.3 -
* P < 0.05 when comparing the percentage of JAK2V617F positivity with normal samples.
** P < 0.05 when comparing the ages of JAK2V617F+ and JAK2V617F- samples within each disease.
Table 2 Chromosomal Abnormalities in MPN and JAK2V617F-Positive Samples
Diagnosis Cases V617F Chromosomal Abnormalities
Ph-MPNs 1 + Monosomy 20
1 + Loss of chromosome Y
1 + Isochromosome of the entire long arm of chromosome 8
1 - Loss of chromosome Y
1 - Chromosomes 9 and 12 translocation at 9p21 and 12p12
Leukocytosis 1 + Deletion of the long arm of chromosome 16 at 16q23
AML 1 + Chromosomes 8 and 21 translocation 8q22 and 21q22
2 + 5q deletion and monosomy 7




1 + Trisomy 8
1 + Trisomy 20
Anemia 1 + Trisomy 8
MDS 1 + Deletion of the long arm of chromosome 5 at breakpoint 5q31
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specific types of hematological diseases, since no
JAK2V617F-positive cases were found in patients with
acute lymphoblastic leukemia, chronic lymphocytic leu-
kemia, chronic myeloid leukemia, multiple myeloma, or
thrombocytopenia. The ages of these patients, except for
those with acute lymphoblastic leukemia, were not sig-
nificantly different from the ages of the patients
described above. Furthermore, all blood or bone marrow
samples from patients (n = 1731) with non-hematologi-
cal diseases were JAK2V617F negative. The majority of
these were from children who possibly have develop-
mental disorders (e.g., Down syndrome, developmental
delay, congenital heart defect, dysmorphic features, fail-
ure to thrive, etc.) due to congenital genetic defects.
There are also a number of samples from adult patients
with infertility or multiple miscarriages. Finally, we
included 267 amniotic fluid samples in this study. These
samples were from pregnant women of advanced mater-
nal age and were originally collected to test possible
genetic abnormality of the fetus. None of these samples
showed any sign of JAK2V617F positivity.
Of the 2895 DNA samples available for analyses,
32 were JAK2V617F positive. These positive samples are
predominantly present in MPN patients but also in a
small fraction of patients with other hematological dis-
eases including AML, anemia, MDS, and lymphoma.
Positive samples were not found at all in health donors
of comparable ages and individuals who did not have
hematological diseases. Thiss u g g e s t sJ A K 2 V 6 1 7 Fp o s i -
tivity is associated with specific hematological malignan-
cies. This, however, does not contradict our previous
data, which revealed the presence of JAK2V617F in
many patients without a MPN phenotype but who had
cerebral and cardiovascular disorders [18]. First, our
current analysis covered a set of clinical samples very
different from our previous study. Second, heart disease
and stroke are often associated with blood abnormality,
although they are not necessarily linked to malignant
blood diseases. We believe the JAK2V617F-induced pre-
MPN phenotype may increase the likelihood of other
blood cell-related diseases. In any case, relevance of
JAK2V617F positivity with vascular disorders deserves
further investigations.
Conclusions
Our data demonstrate that JAK2V617F is predominantly
present in MPN patients and is associated with specific
hematological malignancies (P < 0.05). Our current data
also suggest the nested allele-specific PCR method is
sensitive enough to provide clinically relevant informa-
tion but not so sensitive as to give false or misleading
information [17]. With a sensitivity of about 0.25%
mutation rate, the method is simple, quick, and inex-
pensive [18]. It requires a very small amount of DNA,
and even non-purified DNA of poor quality can be suc-
cessfully analyzed. For these reasons, this test should be
conducted on all cases suspected of having MPNs as
well as on other related diseases.
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